Blood and Marrow Transplant Clinical Trials Network Toxicity Committee Consensus Summary: Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation
Vincent T. Ho(Dana-Farber Cancer Institute), Sergio Giralt(Memorial Sloan Kettering Cancer Center), Shelly Carter(European Society for Blood and Marrow Transplantation), Paul J. Martin(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Robert J. Soiffer(Dana-Farber Cancer Institute), Roberta Adams(Mayo Clinic Health System), James L.M. Ferrara(Tisch Hospital), Mary M. Horowitz(Medical College of Wisconsin), Corey Cutler(Harvard University)
Cited by 458
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k
Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for Leukemia
|New England Journal of Medicine|1986|1.5k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k